Vladimir Torchilin
About Vladimir Torchilin
Vladimir P. Torchilin, Ph.D., D.Sc., MSE, is the Scientific Co‑founder of Immix Biopharma (since inception in 2012), and a University Distinguished Professor of Pharmaceutical Sciences and Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University (since 1998), with prior roles at Massachusetts General Hospital and Harvard Medical School (1993–1997) . As of the 2025 record date he is 78 years old and serves as an executive officer (Scientific Co‑founder) at IMMX; his education includes a Ph.D. and D.Sc. in polymer chemistry and an M.S. in chemistry from Moscow State University . Torchilin has published 400+ original papers, 150+ reviews and book chapters, edited 12 books, holds 40+ patents, has received $30M+ in research funding, and was ranked #2 globally in pharmacology (2000–2010) by Times Higher Education in 2011 . The company’s proxies do not disclose executive‑specific TSR, revenue growth, or EBITDA growth metrics tied to Torchilin’s compensation .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Northeastern University | University Distinguished Professor; Director, Center for Pharmaceutical Biotechnology and Nanomedicine | 1998–present | Leads academic research in pharmaceutical sciences and nanomedicine |
| Massachusetts General Hospital | Head of Chemistry Program, Center for Imaging and Pharmaceutical Research | 1993–1997 | Led chemistry program advancing imaging/pharmaceutical research |
| Harvard Medical School | Associate Professor of Radiology | 1993–1997 | Academic leadership in radiology and translational research |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Current Drug Discovery Technologies | Editor‑in‑Chief | Not disclosed | Editorial leadership shaping drug discovery discourse |
| Drug Delivery | Editor‑in‑Chief | Not disclosed | Advances publication standards in drug delivery |
| OpenNano | Editor‑in‑Chief | Not disclosed | Guides nanotechnology scholarship |
| Current Pharmaceutical Biotechnology | Co‑Editor | Not disclosed | Co‑curates biotechnology research output |
| Multiple journals | Editorial Board Member | Not disclosed | Provides subject‑matter oversight across journals |
Fixed Compensation
- Immix’s Summary Compensation Tables for 2023–2025 list CEO, CFO, and CMO; there is no line item for Vladimir Torchilin, indicating he was not a named executive officer and his base salary/bonus are not disclosed in those proxies .
Performance Compensation
- No performance‑based compensation details (RSUs/PSUs, option awards, targets, or payouts) are disclosed for Torchilin in 2023–2025 proxies; SCT and narrative compensation sections cover CEO, CFO, and CMO only .
Incentive Plan Design Context (Company‑wide, not Torchilin‑specific)
- Company equity plans set standard option maximum 10‑year terms, strike price ≥ fair market value at grant, and provide Administrator adjustment rights for capitalization changes; director total annual comp capped at $300,000 (cash + grant‑date fair value) .
Equity Ownership & Alignment
| Metric | As‑of | Value |
|---|---|---|
| Shares beneficially owned (Torchilin) | April 14, 2023 record date | 905,200 shares |
| Ownership % of shares outstanding | April 14, 2023 record date | 6.5% of 13,948,822 shares outstanding |
| Shares pledged as collateral | As of Dec 31, 2022 / Dec 31, 2023 | None pledged by any directors or executive officers under Insider Trading Policy |
| Hedging and margin/pledging policy | Policy statement | Prohibits short sales, hedging/monetization, derivatives; margin purchases/pledging require pre‑clearance |
- Beneficial ownership tables in 2024 and 2025 proxies list directors/named executive officers and 5% holders; Torchilin appears as a 5%+ holder in 2023 but is not listed among 2024/2025 named directors/NEOs tables excerpted, and the 2025 proxy notes “None” for 5% or greater stockholders as of April 22, 2025 .
- Vested vs unvested shares, option exercisable vs unexercisable counts, and any in‑the‑money value are not disclosed for Torchilin in the proxies reviewed .
Employment Terms
- No employment agreement, severance, non‑compete, or change‑of‑control terms are disclosed for Torchilin in the 2023–2025 proxies; employment agreement disclosures cover the CFO’s Management Services Agreement and the CMO’s hourly arrangement and option grant, with no parallel disclosure for Torchilin .
- Related‑party transactions: the company reports none (above materiality thresholds) since Jan 1, 2024 other than compensation and routine arrangements described elsewhere; no Torchilin‑specific related‑party transactions are disclosed in the 2025 proxy .
Investment Implications
- Alignment: Historical 6.5% beneficial ownership as of 2023 indicates meaningful skin‑in‑the‑game; combined with anti‑hedging/anti‑pledging restrictions and no pledging by executive officers, this reduces misalignment and forced‑sale risk .
- Disclosure gap: Absence of Torchilin‑specific cash/equity compensation detail and lack of vesting schedules or performance metrics limit pay‑for‑performance assessment and modeling of insider‑related selling pressure; monitoring future proxies and any Form 4 activity is prudent .
- Retention/succession watch: At age 78 and with substantial external academic/editorial commitments, governance focus should include succession and continuity of scientific leadership; company documents confirm his continued executive role but do not detail employment terms, severance, or CoC protections that could affect transition dynamics .
- Governance/related‑party risk: The 2025 proxy reports no material related‑party transactions aside from compensation arrangements; combined with the insider trading policy, this supports cleaner governance optics, though ongoing verification remains necessary .